Clinical Trial News and Research

RSS

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

InterMune, Inc. today announced that CHEST, the journal of the American College of Chest Physicians, published an important analysis of variables that measure clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF), a deadly and debilitating lung disease.

10 Jan 2005

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.

10 Jan 2005

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.

9 Jan 2005

FDA clearance to test influenza vaccine, Fluviral

ID Biomedical Corporation announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin immediate clinical testing of its influenza vaccine, Fluviral, in the United States under an Investigational New Drug application (IND).

7 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

Antibiotics protect nerves in mice by turning on genes

A family of antibiotics that includes penicillin may help prevent nerve damage and death in a wide variety of neurological diseases, including Lou Gehrig's disease, dementia, stroke, and epilepsy, Johns Hopkins researchers have found.

6 Jan 2005

Technology that could double the effectiveness of cancer drugs

To identify the best treatment for recurrent ovarian cancer, researchers at Yale School of Medicine are studying a technology called the Yale apoptosis assay in combination with another technology called the ChemoFX assay, which could double the response rate to existing drugs.

4 Jan 2005

Information submitted via new drug applications could easily be made accessible to the public

A researcher at Oregon Health & Science University and the Portland Veterans Affairs Medical Center is calling upon the U.S. Food and Drug Administration (FDA) to share more information provided by pharmaceutical companies regarding their clinical drug trials.

28 Dec 2004

Public health advisory for the use of non-steroidal anti-inflammatory drug products

The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.

23 Dec 2004

Essential oils have been found to kill the deadly MRSA bacteria

Essential oils usually used in aromatherapy have been found to kill the deadly MRSA bacteria according to research carried out at The University of Manchester.

From The University of Manchester 21 Dec 2004

Radon in homes and risk of lung cancer

Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies, BMJ Online First.

21 Dec 2004

Success of surgery for ovarian cancer

Results of the first randomized control trial conducted in the United States to help determine the success of surgery for ovarian cancer have been published in the New England Journal of Medicine.

21 Dec 2004

New advice on anti-inflammatory drugs called Cox-2 Inhibitors, including Celebrex

Patients who are taking Celebrex, Bextra and Arcoxia should make a non-urgent appointment with their GP to review their treatment. Patients who have established heart disease or who are at high risk of stroke will have their treatment changed.

21 Dec 2004

FDA issues advice on Naproxen

The FDA has released the following statement on NIH halting a clinical trial involving non-steroidal anti-inflammatory drugs in patients at risk of developing Alzheimer's Disease:

20 Dec 2004

5000 year old system of medicine provides pain relief for people with osteoarthritis of the knee

A 5000 year old system of medicine, acupuncture provides pain relief and improves function for people with osteoarthritis of the knee and serves as an effective complement to standard care.

20 Dec 2004

Timing of radiation and antiangiogenic therapy impacts treatment effectiveness

Agents designed to attack blood vessels that feed a growing tumor are effective against tumor growth in laboratory experiments. However, results of early clinical trials with these inhibitors have not yet exhibited the same success observed in animal models.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

Detrol LA significantly reduces symptoms of overactive bladder

Pfizer today announced results of a comprehensive six-year review of efficacy and safety data for Detrol LA (tolterodine tartrate extended release capsules) indicating that Detrol LA significantly reduces symptoms of overactive bladder (OAB) with a low occurrence of side effects, and should be considered first-line therapy.

13 Dec 2004

Start today of human tests for a preventive vaccine against the respiratory disease SARS

Powerful research tools that speed up vaccine development have led to the start today of human tests for a preventive vaccine against the respiratory disease SARS. The disease killed hundreds of people around the world before it was brought under control in 2003 with aggressive conventional public health measures.

13 Dec 2004

Clinical Trial News and Research

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

FDA clearance to test influenza vaccine, Fluviral

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Antibiotics protect nerves in mice by turning on genes

Technology that could double the effectiveness of cancer drugs

Information submitted via new drug applications could easily be made accessible to the public

Public health advisory for the use of non-steroidal anti-inflammatory drug products

Essential oils have been found to kill the deadly MRSA bacteria

Radon in homes and risk of lung cancer

Success of surgery for ovarian cancer

New advice on anti-inflammatory drugs called Cox-2 Inhibitors, including Celebrex

FDA issues advice on Naproxen

5000 year old system of medicine provides pain relief for people with osteoarthritis of the knee

Timing of radiation and antiangiogenic therapy impacts treatment effectiveness

Celebrex suspension

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

Detrol LA significantly reduces symptoms of overactive bladder

Start today of human tests for a preventive vaccine against the respiratory disease SARS

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Metabolomics

Improve fermentation and cell culture performance with real-time gas analysis

Scaling patient-derived organoid research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer